92 related articles for article (PubMed ID: 9630477)
1. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus.
Miller AS; Sañudo-Peña MC; Walker JM
Brain Res; 1998 May; 793(1-2):7-11. PubMed ID: 9630477
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid-induced motor incoordination through the cerebellar CB(1) receptor in mice.
DeSanty KP; Dar MS
Pharmacol Biochem Behav; 2001; 69(1-2):251-9. PubMed ID: 11420093
[TBL] [Abstract][Full Text] [Related]
3. Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model.
El-Banoua F; Caraballo I; Flores JA; Galan-Rodriguez B; Fernandez-Espejo E
Neurobiol Dis; 2004 Jul; 16(2):377-85. PubMed ID: 15193294
[TBL] [Abstract][Full Text] [Related]
4. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat.
Sañudo-Peña MC; Walker JM
J Neurophysiol; 1997 Mar; 77(3):1635-8. PubMed ID: 9084627
[TBL] [Abstract][Full Text] [Related]
5. Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound.
Patrini G; Sacerdote P; Fuzio D; Manfredi B; Parolaro D
J Neuroimmunol; 1997 Dec; 80(1-2):143-8. PubMed ID: 9413270
[TBL] [Abstract][Full Text] [Related]
6. Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist.
Gallate JE; Saharov T; Mallet PE; McGregor IS
Eur J Pharmacol; 1999 Apr; 370(3):233-40. PubMed ID: 10334497
[TBL] [Abstract][Full Text] [Related]
7. Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats.
Norwood CS; Cornish JL; Mallet PE; McGregor IS
Eur J Pharmacol; 2003 Mar; 465(1-2):105-14. PubMed ID: 12650839
[TBL] [Abstract][Full Text] [Related]
8. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
Di Marzo V; Hill MP; Bisogno T; Crossman AR; Brotchie JM
FASEB J; 2000 Jul; 14(10):1432-8. PubMed ID: 10877836
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of improgan antinociception by the cannabinoid (CB)(1) antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A): lack of obligatory role for endocannabinoids acting at CB(1) receptors.
Hough LB; Nalwalk JW; Stadel R; Timmerman H; Leurs R; Paria BC; Wang X; Dey SK
J Pharmacol Exp Ther; 2002 Oct; 303(1):314-22. PubMed ID: 12235266
[TBL] [Abstract][Full Text] [Related]
10. Effects of intrapallidal cannabinoids on rotational behavior in rats: interactions with the dopaminergic system.
Sañudo-Peña MC; Walker JM
Synapse; 1998 Jan; 28(1):27-32. PubMed ID: 9414015
[TBL] [Abstract][Full Text] [Related]
11. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus.
Maneuf YP; Nash JE; Crossman AR; Brotchie JM
Eur J Pharmacol; 1996 Jul; 308(2):161-4. PubMed ID: 8840127
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid modulation of rat pup ultrasonic vocalizations.
McGregor IS; Dastur FN; McLellan RA; Brown RE
Eur J Pharmacol; 1996 Oct; 313(1-2):43-9. PubMed ID: 8905327
[TBL] [Abstract][Full Text] [Related]
13. Role of the superior colliculus in the motor effects of cannabinoids and dopamine.
Sañudo-Peña MC; Tsou K; Romero J; Mackie K; Walker JM
Brain Res; 2000 Jan; 853(2):207-14. PubMed ID: 10640618
[TBL] [Abstract][Full Text] [Related]
14. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat.
Martin RS; Secchi RL; Sung E; Lemaire M; Bonhaus DW; Hedley LR; Lowe DA
Psychopharmacology (Berl); 2003 Jan; 165(2):128-35. PubMed ID: 12404071
[TBL] [Abstract][Full Text] [Related]
15. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease.
Sañudo-Peña MC; Patrick SL; Khen S; Patrick RL; Tsou K; Walker JM
Neurosci Lett; 1998 Jun; 248(3):171-4. PubMed ID: 9654336
[TBL] [Abstract][Full Text] [Related]
17. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats.
Romero EM; Fernández B; Sagredo O; Gomez N; Urigüen L; Guaza C; De Miguel R; Ramos JA; Viveros MP
Brain Res Dev Brain Res; 2002 Jun; 136(2):85-92. PubMed ID: 12101025
[TBL] [Abstract][Full Text] [Related]
18. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats.
Wiley JL; Barrett RL; Lowe J; Balster RL; Martin BR
Neuropharmacology; 1995 Jun; 34(6):669-76. PubMed ID: 7566504
[TBL] [Abstract][Full Text] [Related]
19. Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine.
Pertwee RG; Fernando SR; Nash JE; Coutts AA
Br J Pharmacol; 1996 Aug; 118(8):2199-205. PubMed ID: 8864562
[TBL] [Abstract][Full Text] [Related]
20. Regulation of subthalamic neuron activity by endocannabinoids.
Morera-Herreras T; Ruiz-Ortega JA; Taupignon A; Baufreton J; Manuel I; Rodriguez-Puertas R; Ugedo L
Synapse; 2010 Sep; 64(9):682-98. PubMed ID: 20336631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
